MX2021002311A - Metodo para producir un compuesto tetraciclico. - Google Patents

Metodo para producir un compuesto tetraciclico.

Info

Publication number
MX2021002311A
MX2021002311A MX2021002311A MX2021002311A MX2021002311A MX 2021002311 A MX2021002311 A MX 2021002311A MX 2021002311 A MX2021002311 A MX 2021002311A MX 2021002311 A MX2021002311 A MX 2021002311A MX 2021002311 A MX2021002311 A MX 2021002311A
Authority
MX
Mexico
Prior art keywords
producing
tetracyclic compound
producing tetracyclic
compound
carbonitrile
Prior art date
Application number
MX2021002311A
Other languages
English (en)
Spanish (es)
Inventor
Hiroki Serizawa
Akira Kawase
Hiroshi Fukuda
Naoto HAMA
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MX2021002311A publication Critical patent/MX2021002311A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B61/00Other general methods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2021002311A 2018-09-04 2019-09-03 Metodo para producir un compuesto tetraciclico. MX2021002311A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018165313 2018-09-04
PCT/JP2019/034543 WO2020050241A1 (ja) 2018-09-04 2019-09-03 4環性化合物の製造方法

Publications (1)

Publication Number Publication Date
MX2021002311A true MX2021002311A (es) 2021-04-28

Family

ID=69722303

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002311A MX2021002311A (es) 2018-09-04 2019-09-03 Metodo para producir un compuesto tetraciclico.

Country Status (18)

Country Link
US (1) US11939322B2 (https=)
EP (1) EP3848361B1 (https=)
JP (1) JP7167171B2 (https=)
KR (1) KR102635225B1 (https=)
CN (1) CN112585126B (https=)
AR (1) AR116113A1 (https=)
AU (1) AU2019337018B2 (https=)
BR (1) BR112021001145A2 (https=)
CA (1) CA3107270A1 (https=)
ES (1) ES3010145T3 (https=)
HR (1) HRP20250284T1 (https=)
HU (1) HUE070227T2 (https=)
IL (1) IL281079B2 (https=)
MX (1) MX2021002311A (https=)
PL (1) PL3848361T3 (https=)
SG (1) SG11202100983XA (https=)
TW (1) TWI825163B (https=)
WO (1) WO2020050241A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4285907A4 (en) 2021-01-29 2024-11-13 Chugai Seiyaku Kabushiki Kaisha Drug composition for treating pediatric cancers
CN117024410A (zh) * 2023-08-15 2023-11-10 上海药坦药物研究开发有限公司 一种艾乐替尼中间体及其制备方法
WO2025067412A1 (zh) * 2023-09-28 2025-04-03 重庆博腾制药科技股份有限公司 一种抗肿瘤药物中间体的制备方法
CN120081779A (zh) * 2025-02-19 2025-06-03 江苏天士力帝益药业有限公司 一种阿来替尼杂质01a及其控制方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS506987B1 (https=) 1970-02-17 1975-03-19
JPS4918630B1 (https=) 1970-07-29 1974-05-11
JPS5859712U (ja) 1981-10-16 1983-04-22 ニチバン株式会社 ラベル貼付機
JPH0892090A (ja) 1994-07-26 1996-04-09 Tanabe Seiyaku Co Ltd 医薬組成物
EP0695755B1 (en) 1994-08-04 1998-10-21 F. Hoffmann-La Roche AG Pyrrolocarbazole
EA001450B1 (ru) 1996-05-01 2001-04-23 Эли Лилли Энд Компани Галогензамещенные ингибиторы протеинкиназы с
ES2292262T3 (es) * 1998-12-24 2008-03-01 Astellas Pharma Inc. Compuestos de imidazol y su uso medicinal.
EP1178988B1 (en) 1999-05-14 2007-02-28 The Australian National University Compounds and therapeutic methods
GB0030417D0 (en) 2000-12-13 2001-01-24 Pharma Mar Sa An anticancer lead compound isolated from a New Zealand ascidian
FR2841138B1 (fr) 2002-06-25 2005-02-25 Cll Pharma Composition pharmaceutique solide contenant un principe actif lipophile, son procede de preparation
EP1603567A4 (en) 2003-02-28 2006-10-18 Inotek Pharmaceuticals Corp TETRACYCLIC BENZAMIDE DERIVATIVES AND METHOD OF USE THEREOF
ES2263862T3 (es) 2003-03-07 2006-12-16 Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Ensayo de quinasa de linfoma anaplasico, sus reactivos y composiciones.
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
EP1648455A4 (en) 2003-07-23 2009-03-04 Exelixis Inc MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE
US7378414B2 (en) 2003-08-25 2008-05-27 Abbott Laboratories Anti-infective agents
PT1687305E (pt) 2003-11-21 2008-10-17 Novartis Ag Derivados de 1h-imidazoquinolina como inibidores de proteína quinase
JP2007513890A (ja) 2003-12-12 2007-05-31 メルク フロスト カナダ リミテツド カテプシンシステインプロテアーゼ阻害剤
TW200609215A (en) 2004-03-19 2006-03-16 Speedel Experimenta Ag Organic compounds
WO2005092062A2 (en) * 2004-03-19 2005-10-06 Myriad Genetics, Inc. Compounds for neurodegenerative disorders
JP2008502595A (ja) 2004-03-31 2008-01-31 エグゼリクシス, インコーポレイテッド 未分化リンパ腫キナーゼモジュレータおよびその使用方法
MXPA06014066A (es) * 2004-06-02 2007-02-15 Pharmacyclics Inc Inhibicion de factor viia.
DE602005020465D1 (de) 2004-08-26 2010-05-20 Pfizer Enantiomerenreine aminoheteroaryl-verbindungen als proteinkinasehemmer
US7091202B2 (en) 2004-09-15 2006-08-15 Bristol-Myers Squibb Company 4-arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators
GB0517329D0 (en) 2005-08-25 2005-10-05 Merck Sharp & Dohme Stimulation of neurogenesis
RU2008122547A (ru) 2005-11-07 2009-12-20 Айрм Ллк (Bm) Соединения и композиции как модуляторы арпп (активированных рецепторов пролифератора пероксисом)
US7601716B2 (en) 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
US8063225B2 (en) 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
ES2555803T3 (es) 2006-10-23 2016-01-08 Cephalon, Inc. Fusión de derivados bicíclicos 2,4-diaminopirimidina como utilizar inhibidores ALK y c-Met
EP2142551B1 (en) 2007-04-17 2015-10-14 Bristol-Myers Squibb Company Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors
TWI389893B (zh) 2007-07-06 2013-03-21 Astellas Pharma Inc 二(芳胺基)芳基化合物
PT2176231T (pt) 2007-07-20 2016-12-09 Nerviano Medical Sciences Srl Derivados de indazol substituídos activos como inibidores de quinases
US10047066B2 (en) 2007-11-30 2018-08-14 Newlink Genetics Corporation IDO inhibitors
US20110038898A1 (en) 2008-03-13 2011-02-17 Shuichi Yada Dissolution properties of drug products containing olmesartan medoxomil
MX2011011661A (es) 2009-05-07 2011-11-18 Astrazeneca Ab Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
ES2575084T3 (es) 2009-06-10 2016-06-24 Chugai Seiyaku Kabushiki Kaisha Compuesto tetracíclico
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
CN103052386B (zh) 2010-08-20 2016-03-02 中外制药株式会社 含有四环化合物的组合物
JP5006987B2 (ja) 2010-11-22 2012-08-22 中外製薬株式会社 4環性化合物を含む医薬
MY170904A (en) 2012-09-25 2019-09-13 Chugai Pharmaceutical Co Ltd Ret inhibitor
JP6873698B2 (ja) 2014-04-25 2021-05-19 中外製薬株式会社 4環性化合物の新規結晶
TWI831128B (zh) 2014-04-25 2024-02-01 日商中外製藥股份有限公司 以高用量含有4環性化合物的製劑
WO2015193309A1 (en) 2014-06-18 2015-12-23 F. Hoffmann-La Roche Ag New pharmaceutical composition comprising non-ionic surfactants
TWI803187B (zh) 2014-08-08 2023-05-21 日商中外製藥股份有限公司 包含4環性化合物的非晶質體之固體分散體及製劑
CN104402862B (zh) * 2014-11-12 2016-10-05 苏州明锐医药科技有限公司 艾立替尼的制备方法
US9573932B2 (en) 2015-03-02 2017-02-21 Yong Xu Synthesis of intermediates in the preparation of ALK inhibitor
WO2017073706A1 (ja) * 2015-10-30 2017-05-04 中外製薬株式会社 ジヒドロナフト[2,3-b]ベンゾフラン誘導体
CN106928184B (zh) * 2017-04-21 2019-09-20 湖南博奥德药业有限公司 一种艾乐替尼的制备方法
CN106928185B (zh) * 2017-04-21 2019-09-20 湖南博奥德药业有限公司 一种艾乐替尼的制备方法
CN107033124B (zh) * 2017-04-21 2019-09-20 湖南博奥德药业有限公司 一种艾乐替尼的制备方法

Also Published As

Publication number Publication date
CA3107270A1 (en) 2020-03-12
AU2019337018B2 (en) 2024-03-07
IL281079B1 (en) 2024-08-01
HUE070227T2 (hu) 2025-05-28
US20220372025A1 (en) 2022-11-24
WO2020050241A1 (ja) 2020-03-12
CN112585126B (zh) 2024-05-07
HRP20250284T1 (hr) 2025-04-25
AR116113A1 (es) 2021-03-31
EP3848361A1 (en) 2021-07-14
EP3848361C0 (en) 2025-01-22
EP3848361A4 (en) 2022-06-15
EP3848361B1 (en) 2025-01-22
TW202024050A (zh) 2020-07-01
KR20210053890A (ko) 2021-05-12
CN112585126A (zh) 2021-03-30
JPWO2020050241A1 (ja) 2021-08-30
JP7167171B2 (ja) 2022-11-08
IL281079B2 (en) 2024-12-01
PL3848361T3 (pl) 2025-07-07
AU2019337018A1 (en) 2021-03-18
SG11202100983XA (en) 2021-03-30
ES3010145T3 (en) 2025-04-01
BR112021001145A2 (pt) 2021-04-20
IL281079A (en) 2021-04-29
TWI825163B (zh) 2023-12-11
US11939322B2 (en) 2024-03-26
KR102635225B1 (ko) 2024-02-07

Similar Documents

Publication Publication Date Title
MX2021002311A (es) Metodo para producir un compuesto tetraciclico.
ZA202407520B (en) Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
PH12019502673A1 (en) Novel aspartokinase variant and method for producing l-amino acid using the same
JOP20210064B1 (ar) طريقة لانتاج ( z)-ألفا-فلورو-بيتا-أمينو-أكريل الدهيدات مستبدلة
PH12019500493A1 (en) Solvate form of (r)-2-amino-3-phenylpropyl carbamate
SA518400053B1 (ar) عملية مُحسنة لإنتاج حمض أكريليك
MY203897A (en) Methods of producing omega-hydroxylated fatty acid derivatives
PH12018500093A1 (en) Process for the production of cannabidiol and delta-9-tetrahydrocannabinol
MX2016012419A (es) Formas solidas de ibrutinib y procesos para la produccion de las mismas.
MX2015009942A (es) Sintesis de 1,1,2,3-tetracloropropeno.
MY198177A (en) Method For Obtaining Alcohols From Aldehydes III
EP4417605A3 (en) Method for synthesis of eliglustat and intermediate compounds thereof
MY172601A (en) Improved process for preparing fermented soybean meal
TR201907789T4 (tr) Kalkobutrol hazirlanişina yöneli̇k yöntem
MX2021002854A (es) Ciclacion enzimatica de acido homofarnesilico.
SA519410407B1 (ar) طريقة لتحضير مركب وسيط من مشتق 4 - ميثوكسي بيرول
PH12019502616A1 (en) Approval workflow entrusting and re-entrusting methods
MX2020006040A (es) Intermedios para derivados de piperidina opticamente activos y procedimientos de preparacion de los mismos.
MX362102B (es) Método para producir 4-[5-(piridin-4-il)-1h-1,2,4-triazol-3-il]pir idina-2-carbonitrilo e intermediario del mismo.
WO2014152928A3 (en) Processes for producing sovaprevir
EA200870320A1 (ru) Способ получения г-ксф человека
WO2018007973A3 (en) Process and intermediates for preparing benzoxazepines
PH12013500609A1 (en) Novel method of preparing benzoimidazole derivatives
MY209570A (en) Method for preparing aryl 2-tetrazol-2-yl kethone with improved selectivity
SE1551246A1 (en) Modified wood product and a process for producing said product